National cancer incidence and mortality in China, 2012
Cancer is one of the major non-communicable diseases in China and around the world. It is now the leading cause of death, causing about one fourth of all deaths in China. The National Central Cancer Registry (NCCR) is responsible for collecting population-based cancer registration data from local cancer registries for cancer statistics and publishing cancer registry annual report. The cancer registration data are not only widely used for cancer control and decision making, but also for scientific research. In this article, we provide a comprehensive overview of cancer incidence and mortality rates, and estimate new cancer cases and cancer deaths in 2012.
Population-based cancer incidence analysis in Beijing, 2008-2012
The National Central Cancer Registry (NCCR) of China estimated that there were 3,093,039 new cases of cancer diagnosed in 2010 in China. As the capital of China, Beijing is facing a heavy burden of disease due to the rapid economy development and the ageing of population. Cancer has been the leading cause of death in Beijing since 2007 and drawn much attention in public health. The population-based cancer registries (PBCRs) play an important role on estimating the incidence of cancer, and are very useful in the prevention and control of cancer. We reported the incidence of cancer during 1998-2007 in urban Beijing in a previous study. In this paper, we updated the cancer incidence with data from 2008 to 2012 and compared the cancer spectrum with that during 1998-1999.
A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer
This study demonstrates the tolerability of nimotuzumab combined with chemotherapy in Chinese NSCLC patients. The toxicity profile of the nimotuzumab and docetaxel combination appeared favorable, and complications were mild. Grade III–IV toxicities (accounting for 50% of all adverse events) included neutropenia and fatigue, and other toxicities included rash (occurred in only one patient). DLT occurred with Grade 3 fatigue at the 200 mg dose level of nimotuzumab and Grade 4 neutropenia with pneumonia at the 600 mg dose level of nimotuzumab.
Heat shock protein inhibitor, quercetin, as a novel adjuvant agent to improve radiofrequency ablation-induced tumor destruction and its molecular mechanism
In the present study, we reported that combining RFA with adjuvant quercetin-loaded liposomes increased tumor cell death by limiting the actions of transcription factor HSF1 and subsequently inhibiting HSP70 and thereby resulting in improved clinical outcomes. Consistently, blocking HSF1 in vitro (via siRNA mediated knockdown) improved the therapeutic outcomes when used in combination with heat. Intriguingly, the actions of quercetin that improved the clinical outcomes in the combination therapy with RF appeared to require the AP-1 signaling pathways.